Clinical Staging System by Blood Chemical Examination in Patients with Hepatocelluar Carcinoma

臨床生化学検査による肝細胞癌患者の臨床病期分類

Clinical Staging System by Blood Chemical Examination in Patients with Hepatocelluar Carcinoma

Creators Nawata Junsuke

Blood chemical data were analyzed in patients with hepatocelluar carcinoma (HCC) in order to establish the objective clinical staging system. Conventionally, clinical stages were divided into 5 stages which consisted of stage Ⅴ (15 days before death), stage Ⅳ (16 to 30 days), stage Ⅲ (31 to 60 days), stage Ⅱ (61 to 120 days) and stage Ⅰ(more than 121 days). 10 parameters were selected from 73 patients with HCC for discriminant anapysis, which consisted of WBC, lymphocytes, hemoglobin, albumin, γ-globulin, bilirubin, ALP, GOT, serum protein and urea-N. 123 cases were discriminated in each clinical stage by multivariate analysis. Discriminant analyses verified 74% of the stage Ⅴ cases, and 94% of those not belonging to stage Ⅴ, 68% of the stage Ⅳ cases, 49% of the stage Ⅲ cases, 65% of the stage Ⅱ cases and 63% of the stage Ⅰ cases. It suggests that blood chemical data are available to discriminate in clinical stages in patients with HCC by multivariate analysis.

[ISSN]0513-1731

[NCID]AN00243156